URITAB XL Tablets / Extended Release
Alfuzosin
10mg
Tabuk Pharmaceutical Manufacturing Co.
| Pack size | 30's (10's Blister x 3) |
|---|---|
| Dispensing mode | POM |
| Source | SAUDI ARABIA |
| Agent | ALPHAMED CO. (AUH) LTD. |
| Retail Price | 85.50 AED |
Indications
URITAB XL Tablets / Extended Release is used for:
Benign prostatic hyperplasia (BPH)
Adult Dose
Oral
Benign prostatic hyperplasia
Adult: 2.5 mg tid. Max: 10 mg/day. 1st dose should be given before bedtime. Extended-release: 10 mg once daily.
Elderly: Initially, 2.5 mg bid. Acute urinary retention: Extended-release: 10 mg once daily to be taken from 1st day of catheterisation. Duration: 3-4 days.
Hepatic impairment: Mild to moderate: Initially, 2.5 mg daily, may increase to 2.5 mg bid according to response. Severe: Contraindicated.
Child Dose
Renal Dose
Renal Impairment Initially, 2.5 mg bid. Adjust dose according to response.
Administration
Administration Should be taken with food. Swallow whole.
Extended-Release: Should be taken with food. Take immediately after the same meal each day. Swallow whole, do not chew/crush.
Contra Indications
Severe hepatic impairment; history of postural hypotension and micturition syncope; intestinal occlusion; severe renal insufficiency; lactation.
Precautions
Elderly; hypertension; coronary insufficiency; angina (discontinue); renal or hepatic impairment. Monitor BP regularly. May affect ability to drive or operate machinery.
Pregnancy-Lactation
Pregnancy Category: B
Lactation: Not indicated for use in women
Interactions
Additive effect on QT interval prolongation when used w/ QT-prolonging drugs. Concomitant admin w/ other ?1-adrenergic blocking agents, atenolol or diltiazem may result in additive CV effects. Increased plasma alfuzosin concentrations w/ cimetidine.
Potentially Fatal: Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir) increase plasma alfuzosin levels.
Adverse Effects
Side effects of Alfuzosin :
1-10%
Abdominal pain (1-2%), Back pain (1-2%), Brochitis (1-2%), Constipation (1-2%), Dizziness (5.7%), Dyspepsia (1-2%), Fatigue (2.7%), Headache (3%), Impotence (1-2%), Nausea (1-2%), Pharyngitis (1-2%), URT infection (3%), Sinusitis (1-2%), Upper respiratory infection (3%)
Mechanism of Action
Alfuzosin is a quinazoline derivative which exhibits selectivity for alpha1-adrenergic receptors in the lower urinary tract. Blockade of these adrenoreceptors causes relaxation of smooth muscle in the bladder neck and prostate, resulting in improvement in urine flow and a reduction in symptoms of benign prostatic hyperplasia (BPH).
Note
URITAB XL 10mg Tablets / Extended Release manufactured by Tabuk Pharmaceutical Manufacturing Co.. Its generic name is Alfuzosin. URITAB XL is availble in United Arab Emirates.
Farmaco UAE drug index information on URITAB XL Tablets / Extended Release is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.